Table 1.
Characteristics of the 105 patients, n (%)
|
Characteristics of the 105 patients
| |
| Demographic and anthropometric data | |
| Sex (male) | 51 (49) |
| Age (yr) | 56 ± 14 |
| BMI (kg/m2) | 31 ± 6 |
| Overweight | 94 (90) |
| Obesity | 50 (48) |
| Waist circumference (cm)1 | 107 ± 15 |
| Diabetes | 38 (36) |
| Hypertension | 42 (40) |
| Metabolic syndrome | 73 (70) |
| Biological data | |
| Platelets count (G/L)1 | 231 ± 72 |
| AST (U/L)1 | 35 ± 28 |
| ALT (U/L)1 | 65 ± 49 |
| GGT (U/L)1 | 120 ± 125 |
| Triglycerides (g/L)1 | 1.7 ± 0.93 |
| HDL cholesterol (g/L)1 | 1.3 ± 0.4 |
| Ferritin (ng/mL)1 | 232 ± 283 |
| Steatosis assessment | |
| PDFF (%)1 | 15 ± 10 |
| Steatosis on MRI | 85 (81) |
| Fibroscan® | |
| Technical success | 104 (99) |
| cCAP (dB/m) | 283 ± 58 |
| Liver stiffness (KPa)1 | 8 ± 7 |
| Liver stiffness > 10 KPa | 21 (20) |
| Use of M probe | 83 (80) |
| Use of XL probe | 21 (20) |
| Aixplorer MACH 30® | |
| Technical success | 105 (100) |
| SSE (m/s)1 | 1519 ± 22 |
| AC (dB/cm/MHz)1 | 0.48 ± 0.1 |
| HRI1 | 1.43 ± 0.28 |
| Technical success | 104 (99) |
1
Data are mean ± SD.
BMI: Body mass index; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma glutamyl transferase; PDFF: Proton density fat fraction; cCAP: Continuous controlled attenuation parameter; SSE: Sound speed estimation; AC: Attenuation coefficient; HRI: Hepato-renal index.